470484-70-9

Basic information

• Product Name: 6-BROMO-1-CHLOROPHTHALAZINE
• Synonyms: 6-BROMO-1-CHLOROPHTHALAZINE;6-BroMo-1-chloro-phthalaz...;PHTHALAZINE, 6-BROMO-1-CHLORO
• CAS NO: 470484-70-9
• Molecular Formula: C₈H₄BrClN₂
• Molecular Weight: 243.5
• Mol File: 470484-70-9.mol
• Article Data: 8

Chemical Properties

• Boiling Point: 419.2±25.0 °C(Predicted)
• Appearance: /
• Density: 1.762±0.06 g/cm3(Predicted)
• PKA: 0.78±0.30(Predicted)
• CAS DataBase Reference: 6-BROMO-1-CHLOROPHTHALAZINE(CAS DataBase Reference)
• NIST Chemistry Reference: 6-BROMO-1-CHLOROPHTHALAZINE(470484-70-9)
• EPA Substance Registry System: 6-BROMO-1-CHLOROPHTHALAZINE(470484-70-9)

Safety Data

• Hazardous Substances Data: 470484-70-9(Hazardous Substances Data)

Usage

General Description

6-Bromo-1-chlorophthalazine is a chemical compound with the molecular formula C8H5BrClN2O2. 6-BROMO-1-CHLOROPHTHALAZINE is a derivative of phthalazine and is commonly used in pharmaceutical research and development. It is known for its potential applications as an intermediate in the synthesis of various biologically active compounds. 6-Bromo-1-chlorophthalazine has been studied for its potential as a building block in the synthesis of new drugs, particularly in the field of anti-inflammatory and antihypertensive medications. Its unique chemical structure and reactivity make it an important and versatile compound in the field of medicinal chemistry.

Upstream product

• 75884-70-7 6-bromophthalazin-1-ol 
• 75884-70-7 6-bromophthalazin-1(2H)-one 
• 64169-34-2 5-bromophthalide 
• 102126-70-5 5-bromo-3-bromo-3H-isobenzofuran-1-one 

Downstream Products

• 794591-70-1 6-bromo-N-(4-trifluoromethylphenyl)-1-phthalazinamine 
• 909186-42-1 6-bromo-N-cyclohexylphthalazin-1-amine 
• 909186-04-5 3-(1-chloro-6-phthalazinyl)-N-cyclopropyl-4-methylbenzamide 
• 918811-38-8 6-bromophthalazin-1-amine 

Relevant articles and documents

Protozoan Parasite Growth Inhibitors Discovered by Cross-Screening Yield Potent Scaffolds for Lead Discovery

Tropical protozoal infections are a significant cause of morbidity and mortality worldwide; four in particular (human African trypanosomiasis (HAT), Chagas disease, cutaneous leishmaniasis, and malaria) have an estimated combined burden of over 87 million disability-adjusted life years. New drugs are needed for each of these diseases. Building on the previous identification of NEU-617 (1) as a potent and nontoxic inhibitor of proliferation for the HAT pathogen (Trypanosoma brucei), we have now tested this class of analogs against other protozoal species: T. cruzi (Chagas disease), Leishmania major (cutaneous leishmaniasis), and Plasmodium falciparum (malaria). Based on hits identified in this screening campaign, we describe the preparation of several replacements for the quinazoline scaffold and report these inhibitors' biological activities against these parasites. In doing this, we have identified several potent proliferation inhibitors for each pathogen, such as 4-((3-chloro-4-((3-fluorobenzyl)oxy)phenyl)amino)-6-(4-((4-methyl-1,4-diazepan-1-yl)sulfonyl)phenyl)quinoline-3-carbonitrile (NEU-924, 83) for T. cruzi and N-(3-chloro-4-((3-fluorobenzyl)oxy)phenyl)-7-(4-((4-methyl-1,4-diazepan-1-yl)sulfonyl)phenyl)cinnolin-4-amine (NEU-1017, 68) for L. major and P. falciparum.

PHTHALAZINE COMPOUNDS AS p38 MAP KINASE MODULATORS AND METHODS OF USE THEREOF

The present invention comprises a new class of compounds useful for the prophylaxis and treatment of protein kinase mediated diseases, including inflammation and related conditions. The compounds have a general Formula I wherein A4, L, R1, R2, R3, R5 and m are as defined herein. The invention also comprises pharmaceutical compositions including one or more compounds of Formula I, uses of such compounds and compositions for treatment of p38 map kinase mediated diseases including rheumatoid arthritis, psoriasis, chronic obstructive pulmonary disease, ankylosing spondylitis, pain and other inflammatory disorders, as well as intermediates and processes useful for the preparation of compounds of Formula I.

PHTHALAZINE, AZA- AND DIAZA-PHTHALAZINE COMPOUNDS AND METHODS OF USE

The present invention comprises a new class of compounds useful for the prophylaxis and treatment of protein kinase mediated diseases, including inflammation and related conditions. The compounds have a general Formula I wherein A1, A2/su